Correlation Between Day One and Innate Pharma

Can any of the company-specific risk be diversified away by investing in both Day One and Innate Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Day One and Innate Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Day One Biopharmaceuticals and Innate Pharma, you can compare the effects of market volatilities on Day One and Innate Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Day One with a short position of Innate Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Day One and Innate Pharma.

Diversification Opportunities for Day One and Innate Pharma

-0.32

Correlation Coefficient

Day One  Innate Pharma

Very good diversification

The 3 months correlation between Day and Innate is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding Day One Biopharmaceuticals and Innate Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Innate Pharma and Day One is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Day One Biopharmaceuticals are associated (or correlated) with Innate Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Innate Pharma has no effect on the direction of Day One i.e., Day One and Innate Pharma go up and down completely randomly.

Pair Corralation between Day One and Innate Pharma

Given the investment horizon of 90 days Day One Biopharmaceuticals is expected to under-perform the Innate Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Day One Biopharmaceuticals is 1.19 times less risky than Innate Pharma. The stock trades about -0.16 of its potential returns per unit of risk. The Innate Pharma is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  211.00  in Innate Pharma on December 26, 2024 and sell it today you would lose (30.00) from holding Innate Pharma or give up 14.22% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Day One Biopharmaceuticals  vs.  Innate Pharma

Day One Biopharmaceu

Risk-Adjusted Performance

Very Weak

Over the last 90 days Day One Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Innate Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's technical indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Day One and Innate Pharma

The main advantage of trading using opposite Day One and Innate Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Day One position performs unexpectedly, Innate Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innate Pharma will offset losses from the drop in Innate Pharma's long position.

The idea behind Day One Biopharmaceuticals and Innate Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.